Renal Cell Carcinoma (RCC) Treatments
Find Renal Cell Carcinoma (RCC) Treatments
Medications for Renal Cell Carcinoma (RCC)
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Renal Cell Carcinoma (RCC).
Found 16 Approved Drugs for Renal Cell Carcinoma (RCC)
Nivolumab
Brand Names
Opdivo, Opdivo QVANTIG, Opdualag
Nivolumab
Brand Names
Opdivo, Opdivo QVANTIG, Opdualag
Form: Injection
Method of administration: Subcutaneous, Intravenous
FDA approval date: December 22, 2014
Classification: Programmed Death Receptor-1 Blocking Antibody
OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab.
Sutent
Generic Name
Sunitinib
Sutent
Generic Name
Sunitinib
Form: Capsule
Method of administration: Oral
FDA approval date: January 26, 2006
Classification: Kinase Inhibitor
SUTENT is a kinase inhibitor indicated for: treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate.
Bevacizumab
Brand Names
Alymsys, Avastin, Avzivi, Avzivi tnjn, Jobevne, MVASI, Vegzelma, Zirabev
Bevacizumab
Brand Names
Alymsys, Avastin, Avzivi, Avzivi tnjn, Jobevne, MVASI, Vegzelma, Zirabev
Form: Injection
Method of administration: Intravenous, Intravascular
FDA approval date: February 26, 2004
Classification: Vascular Endothelial Growth Factor Inhibitor
Alymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment.
Sorafenib
Brand Names
Nexavar, Sorafenib Tosylate
Sorafenib
Brand Names
Nexavar, Sorafenib Tosylate
Form: Tablet
Method of administration: Oral
FDA approval date: December 20, 2005
Classification: Kinase Inhibitor
NEXAVAR is a kinase inhibitor indicated for the treatment of Unresectable hepatocellular carcinoma.
Pembrolizumab
Brand Names
Keytruda, Keytruda QLEX
Pembrolizumab
Brand Names
Keytruda, Keytruda QLEX
Form: Injection
Method of administration: Subcutaneous, Intravenous
FDA approval date: January 15, 2015
Classification: Programmed Death Receptor-1 Blocking Antibody
KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma.
Showing 1-5 of 16
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances